Scope Fluidics Spolka Akcyjna's EBIT per Share for the
three
months ended in Mar. 2026 was zł-4.21.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł-14.26.
During the past 3 years, the average EBIT per Share Growth Rate was -16.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -31.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Scope Fluidics Spolka Akcyjna's EBIT per Share or its related term are showing as below:
WAR:SCP'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -46.2 Med: -32.1 Max: -16.9
Current: -16.9
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Scope Fluidics Spolka Akcyjna was -16.90% per year. The lowest was -46.20% per year. And the median was -32.10% per year.
WAR:SCP's 3-Year EBIT Growth Rate is ranked worse than 81.44% of 167
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.2
vs WAR:SCP: -16.90
Scope Fluidics Spolka Akcyjna (WAR:SCP) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Scope Fluidics Spolka Akcyjna EBIT per Share Related Terms
Scope Fluidics Spolka Akcyjna EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scope Fluidics Spolka Akcyjna EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-14.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scope Fluidics Spolka Akcyjna (WAR:SCP) has a EBIT per Share of zł-14.26 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. According to the industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #136 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 81.4%.
Is Scope Fluidics Spolka Akcyjna's EBIT per Share too high?
Scope Fluidics Spolka Akcyjna's current EBIT per Share is zł-14.26. Based on the distribution chart, Scope Fluidics Spolka Akcyjna ranks #136 out of 167 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Scope Fluidics Spolka Akcyjna has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scope Fluidics Spolka Akcyjna's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Scope Fluidics Spolka Akcyjna ranks #136 out of 167 companies for EBIT per Share. This places Scope Fluidics Spolka Akcyjna in the lower half of its industry. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Scope Fluidics Spolka Akcyjna and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scope Fluidics Spolka Akcyjna's current EBIT per Share is zł-14.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scope Fluidics Spolka Akcyjna stock overvalued right now?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna (WAR:SCP) is currently considered Fairly Valued. The stock's GF Value™ is zł129.40, compared to a current price of zł122.00 — trading 5.7% below its estimated fair value. The current EBIT per Share is zł-14.26. Scope Fluidics Spolka Akcyjna's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Scope Fluidics Spolka Akcyjna (WAR:SCP), the current EBIT per Share is zł-14.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scope Fluidics Spolka Akcyjna (WAR:SCP) Overvalued in 2026?
Based on GuruFocus' analysis, Scope Fluidics Spolka Akcyjna stock appears to be undervalued.
The current stock price of zł122.00 is trading 5.7% below its estimated GF Value™ of zł129.40.
GuruFocus considers Scope Fluidics Spolka Akcyjna to be Fairly Valued.
Key valuation signals for WAR:SCP:
EBIT per Share: zł-14.26
GF Value™: zł129.40 vs. price of zł122.00 (5.7% below fair value)
No single metric tells the full story. See the WAR:SCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scope Fluidics Spolka Akcyjna Business Description
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
48GF Score
Get the complete analysis for WAR:SCP
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCP has been successfully added to your 
